Tranquil Clinical Research

Executive Summary

Tranquil Clinical Research is a US-based Contract Research Organization (CRO) specializing in early-phase clinical trials, with a dedicated Phase I unit in Houston, Texas. Founded in 2015, the company offers full-service capabilities from study start-up to closeout, including functional service provider (FSP) arrangements and a unique sponsor oversight model. Its expertise spans clinical operations, data management, safety, and regulatory compliance, serving pharmaceutical and biotech clients. As a private company, Tranquil Clinical Research is well-positioned to capitalize on the growing demand for outsourced early-phase trial services, though its private nature limits public visibility. The company's focus on neuroscience and Phase I studies provides a niche advantage, but it faces competition from larger CROs. Overall, Tranquil Clinical Research appears to be a stable but modest player in the clinical research space, with potential for growth through strategic partnerships and pipeline expansion.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership for Phase I trial services40% success
• Q3 2026Expansion of Phase I unit capacity or facility upgrade30% success
• Q3 2026New regulatory certification (e.g., FDA inspection clearance) enhancing credibility20% success